Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adebrelimab + chidamide + gemcitabine + S-1
- Development stage
- Unknown
- Lead developer
- Hengrui Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of adebrelimab (likely an immune checkpoint inhibitor), chidamide (likely an epigenetic modulator), gemcitabine (a nucleoside analog used in cancer chemotherapy), and S-1 (an oral fluoropyrimidine anticancer drug). The gemcitabine and S-1 component has shown efficacy in treating biliary tract cancer and pancreatic cancer.
- Brand names
- Airuika
- Other names
- SHR-1316 + chidamide + gemcitabine + S-1Adebrelimab and Chidamide Combined with Gemcitabine and S1
02
Targets
DNADPYD (Dihydropyrimidine dehydrogenase)HDAC1 (Histone Deacetylase 1)HDAC10 (Histone Deacetylase 10)HDAC2 (Histone deacetylase 2)HDAC3 (Histone Deacetylase 3)OPRT (Orotidine 5'-phosphate decarboxylase)CD274 (Programmed cell death protein 1 ligand 1)RNR (Ribonucleotide reductase)TS (Thymidylate synthase)PDCD1 (Programmed cell death protein 1 receptor)Neuraminidase
Beyond the preview
Go deeper on adebrelimab + chidamide + gemcitabine + S-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adebrelimab + chidamide + gemcitabine + S-1.